WO2007056016A3 - Bisamide cytokine inhibitors - Google Patents

Bisamide cytokine inhibitors Download PDF

Info

Publication number
WO2007056016A3
WO2007056016A3 PCT/US2006/042679 US2006042679W WO2007056016A3 WO 2007056016 A3 WO2007056016 A3 WO 2007056016A3 US 2006042679 W US2006042679 W US 2006042679W WO 2007056016 A3 WO2007056016 A3 WO 2007056016A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytokine inhibitors
bisamide
compounds
useful
agents
Prior art date
Application number
PCT/US2006/042679
Other languages
French (fr)
Other versions
WO2007056016A2 (en
Inventor
Nancy G L Delaet
Antonio Garrido Montalban
Christopher Larson
Christopher Lum
Yazhong Pei
Lubomir Sebo
Jan Urban
Zhijun Wang
Erik Boman
Original Assignee
Kemia Inc
Nancy G L Delaet
Antonio Garrido Montalban
Christopher Larson
Christopher Lum
Yazhong Pei
Lubomir Sebo
Jan Urban
Zhijun Wang
Erik Boman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc, Nancy G L Delaet, Antonio Garrido Montalban, Christopher Larson, Christopher Lum, Yazhong Pei, Lubomir Sebo, Jan Urban, Zhijun Wang, Erik Boman filed Critical Kemia Inc
Publication of WO2007056016A2 publication Critical patent/WO2007056016A2/en
Publication of WO2007056016A3 publication Critical patent/WO2007056016A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are bisamides and are useful as anti-inflammatory agents. In one aspect the compounds have the structure of Formula (I) as defined herein. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines, such as for example arthritis, pain, and cancer.
PCT/US2006/042679 2005-11-02 2006-11-01 Bisamide cytokine inhibitors WO2007056016A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73292405P 2005-11-02 2005-11-02
US60/732,924 2005-11-02
US79006206P 2006-04-07 2006-04-07
US60/790,062 2006-04-07

Publications (2)

Publication Number Publication Date
WO2007056016A2 WO2007056016A2 (en) 2007-05-18
WO2007056016A3 true WO2007056016A3 (en) 2009-04-30

Family

ID=38023789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/042679 WO2007056016A2 (en) 2005-11-02 2006-11-01 Bisamide cytokine inhibitors

Country Status (1)

Country Link
WO (1) WO2007056016A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116145A2 (en) * 2007-03-22 2008-09-25 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
CL2008001943A1 (en) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compounds derived from phenyl-triazole, inhibitors of specific signal enzymes that participate in the control of cell proliferation; pharmaceutical composition comprising said compounds; and its use to treat cancer, infections, inflammatory and autoimmune diseases.
JP2011524365A (en) * 2008-06-11 2011-09-01 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions useful for the treatment of malaria
AR073501A1 (en) 2008-09-08 2010-11-10 Boehringer Ingelheim Int PYRIMID DERIVATIVES [5,4-D] PYRIMIDINE INHIBITORS OF THYROSINOQUINASE
WO2010034838A2 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
JP5603883B2 (en) 2009-02-17 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrimidopyrimidine derivatives for inhibiting B-Raf kinase
BRPI1011247A2 (en) 2009-06-09 2016-06-21 California Capital Equity Llc isoquinoline, quinoline and quinazoline derivatives as hedgehog signaling inhibitors
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc Benzyl substituted triazine derivatives and their therapeutical applications
BRPI1011318A2 (en) 2009-06-09 2019-09-24 California Capital Equity Llc triazine derivatives and their therapeutic applications
JP2011057661A (en) * 2009-08-14 2011-03-24 Bayer Cropscience Ag Pesticidal carboxamides
JP5871896B2 (en) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング B-RAF kinase inhibitor
JP5871897B2 (en) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyridyltriazole
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
DE112012003510T5 (en) 2011-10-21 2015-03-19 Abbvie Inc. Method for the treatment of HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
PT107924A (en) 2011-10-21 2014-12-03 Abbvie Inc TREATMENT OF AAD COMBINATION (EG WITH ABT-072 OR ABT-333) FOR USE IN HCV TREATMENT
CA2896554C (en) * 2012-12-27 2019-11-05 Drexel University Novel antiviral agents against hbv infection
JP6777904B2 (en) * 2015-10-28 2020-10-28 一般社団法人ファルマバレープロジェクト支援機構 New anti-cancer drug
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses
SG10202110259QA (en) 2017-10-05 2021-10-28 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2020176289A1 (en) * 2019-02-25 2020-09-03 The University Of Toledo Pegylated bilirubin for the treatment of hyperlipidemia, obesity, fatty liver disease cardiovascular diseases and type ii diabetes
CN112824387B (en) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 2-methyl nicotinate and preparation method and application thereof
CN113209112B (en) * 2021-02-06 2021-12-24 广州市朝利良生物科技有限公司 Novel coronavirus resistant medicine based on ACE2 and S protein binding target and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329526B1 (en) * 1996-01-11 2001-12-11 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US7285545B2 (en) * 2004-05-03 2007-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329526B1 (en) * 1996-01-11 2001-12-11 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US7285545B2 (en) * 2004-05-03 2007-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors

Also Published As

Publication number Publication date
WO2007056016A2 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2007056016A3 (en) Bisamide cytokine inhibitors
WO2005023761A3 (en) Cytokine inhibitors
WO2007075896A3 (en) Heterocyclic cytokine inhibitors
WO2008089034A3 (en) Cytokine inhibitors
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
WO2006028525A3 (en) [3.2.0] heterocyclic compounds and methods of using the same
UA91007C2 (en) Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2006073457A8 (en) Bioactive compounds and methods of uses thereof
MXPA05012025A (en) Imidazo and thiazolopyridines as jak3 kinase inhibitors.
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2008057512A3 (en) Imidazopyrazines as protein kinase inhibitors
DK1420801T3 (en) Use of fucans for the treatment of adhesions, arthritis and psoreasis
UA91002C2 (en) 7-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-polymerase inhibitors
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
ATE413388T1 (en) MUSCARINE ANTAGONISTS
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
MX2010007392A (en) Trpa1 antagonists.
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
SE0302139D0 (en) Novel compounds
WO2006093832A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2007066337A3 (en) Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06827298

Country of ref document: EP

Kind code of ref document: A2